Inventor · disambiguated record
Michael Nebozhyn
Also filed as: NEBOZHYN III MICHAEL · NEBOZHYN MICHAEL · NEBOZHYN MICHAEL V
8 granted patents·14 pending applications·25 citations·filing 2004–2023
82Inventor score
Files withMERCK SHARP & DOHME6H LEE MOFFITT CANCER CT & RES4LOBODA ANDREY3MERCK SHARP & DOHME LLC2WISTAR INST2
Top patents by PatentIndex Score
22 records- 0182US10041129B2Immune gene signatures in cancerH LEE MOFFITT CANCER CT & RES·Filed 2016·Granted Aug 7, 2018·3 cites·15 claims
- 0282US7514219B2Method for distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinomaWISTAR INST·Filed 2006·Granted Apr 7, 2009·4 cites·4 claims
- 0380US10648040B2Immune gene signatures in treating breast cancerH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted May 12, 2020·1 cites·15 claims
- 0480US7640114B2Method of diagnosis of cancer based on gene expression profiles in cellsWISTAR INST·Filed 2004·Granted Dec 29, 2009·10 cites·20 claims
- 0577US9404926B2Immune gene signatures in cancerMULÉ JAMES J·Filed 2011·Granted Aug 2, 2016·5 cites·21 claims
- 0671US2021381061A1Immune Gene Signatures in CancerH LEE MOFFITT CANCER CT & RES·Filed 2021·Application pending·0 cites
- 0770US8392127B2Methods and gene expression signature for assessing growth factor signaling pathway regulation statusWATTERS JAMES·Filed 2009·Granted Mar 5, 2013·2 cites·7 claims
- 0868US2025356947A1Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage diseaseMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 0967US2020399706A1Immune Gene Signatures in CancerH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 1055US2024247065A1Methods of treatment of cancer patients having altered setd2 biomarker with a pd-1 antagonistMERCK SHARP & DOHME LLC·Filed 2022·Application pending·0 cites
- 1154US2014030255A1Methods of predicting cancer cell response to therapeutic agentsLOBODA ANDREY·Filed 2011·Application pending·0 cites
- 1250US2014031251A1Methods of classifying human subjects with regard to cancer prognosisYEATMAN TIMOTHY·Filed 2011·Application pending·0 cites
- 1348US2022380854A1ANGIOGENESIS AND mMDSC GENE EXPRESSION BASED BIOMARKER OF TUMOR RESPONSE TO PD-1 ANTAGONISTSMERCK SHARP & DOHME·Filed 2020·Application pending·0 cites
- 1446US2024317854A1Methods for treating cancer with anti-ilt3 antibodiesBRANDISH PHILIP E·Filed 2022·Application pending·0 cites
- 1546US2016312297A1Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonistsMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 1645US2022112564A1Gene expression based biomarker of tumor response to pd-1 antagonistsLOBODA ANDREY·Filed 2020·Application pending·0 cites
- 1744US2016312295A1Gene signature biomarkers of tumor response to pd-1 antagonistsMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 1844US2016304969A1Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonistsMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 1943US2014304845A1Alzheimer's disease signature markers and methods of useMERCK SHARP & DOHME·Filed 2012·Application pending·0 cites
- 2042US11326211B2Blood-based biomarkers of tumor sensitivity to PD-1 antagonistsMERCK SHARP & DOHME·Filed 2016·Granted May 10, 2022·0 cites·18 claims
- 2135US2010280987A1Methods and gene expression signature for assessing ras pathway activityLOBODA ANDREY·Filed 2010·Application pending·0 cites
- 2227US11377693B2System and methods for deriving gene signature biomarkers of response to PD-1 antagonistsAYERS MARK D·Filed 2015·Granted Jul 5, 2022·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Michael Nebozhyn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →